Windgap Medical, Inc. products

The ANDIPEN is a wet/dry dual-chamber autoinjector built to drastically improve temperature resilience and shelf lives of medications traditionally offered and stored in liquid form. The ANDI® Platform is the basis for our epinephrine product, currently in pre-production in partnership with ALK-Abelló.

This device is supported by an ongoing NIH grant and potential for follow-on funding.

Windgap’s autoinjector offers an approved dosage that can be performed accurately, easily, and instantly by anyone—even a patient in the early stages of hypoglycemic crisis.

Our thermally stable drug delivery platform will automate rehydration and administration with twice the shelf life and half the size of current anaphylaxis treatments.

Funded by a grant from the National Institutes of Health, Windgap Medical has partnered with the University of Minnesota to develop an emergency treatment autoinjector for first responders and fire victims exposed to cyanide through smoke inhalation.

Liquid medications typically have a poor stability profile. Our wet-dry autoinjectors contain drugs in their most stable state, offering unprecedented temperature resilience, shelf life, and patient compliance.

Lyophilized drugs can require multiple complicated steps—and take over two minutes—to administer a life-saving dose of rescue glucagon. Our self-administered ANDI® platform does it in two steps—and in seconds.

Current long-acting injectables require complicated preparation steps, often with dosing and degradation issues. Our in-device mixing mechanisms automate and control this process to protect the medication, the patient, and the outcome.